A Self-Monitoring Platform for Tracking Medication Safety and Concerns in Cancer Patients
This clinical trial evaluates the usefulness of a self-monitoring platform for tracking medication safety events and concerns in patients with lung, colorectal, breast, and prostate cancer. Patients receiving oral anticancer agents often encounter challenges in managing complex treatment regimens, potentially life-threatening toxicities, and drug-drug and drug-food interactions at home. To achieve the goal of medication safety, they need to become "vigilant partners" in medication and toxicity self-monitoring…
Conditions studied
Breast Carcinoma, Colorectal Carcinoma, Lung Carcinoma, Malignant Solid Neoplasm, Prostate Carcinoma
About this study
This clinical trial evaluates the usefulness of a self-monitoring platform for tracking medication safety events and concerns in patients with lung, colorectal, breast, and prostate cancer. Patients receiving oral anticancer agents often encounter challenges in managing complex treatment regimens, potentially life-threatening toxicities, and drug-drug and drug-food interactions at home. To achieve the goal of medication safety, they need to become "vigilant partners" in medication and toxicity self-monitoring, including timely reporting of medication events to clinicians when their care transitions back home. In this study, patients use an online self-monitoring platform to track their experiences or concerns about taking their medications, including their experiences with symptoms. This platform may be a useful way for patients to track problems they have when taking their medications at home and may help them take better care of their health.
Interventions
- Other: Educational Intervention — Receive educational materials and resources
- Other: Electronic Health Record Review — Ancillary studies
- Procedure: Follow-Up — Receive follow-up contact
- Other: Internet-Based Intervention — Use self-monitoring platform
- Other: Interview — Ancillary studies
- Other: Survey Administration — Ancillary studies
Primary outcomes
- Self-reported system usability (Up to 6 months)
- Perceived usefulness (Up to 6 months)
- Ease of use (Up to 6 months)
- Attitudes toward use (Up to 6 months)
- Intention to use and continuous use of the system over time (Up to 12 months)
- Self-reported patient engagement (Up to 6 months)
- System usage over time (Up to 12 months)
- Patient activation levels (Up to 6 months)
Eligibility information
Study locations
- University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan 48109 United States
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-10-20.